311 West Superior Street
Suite 444
Chicago, IL 60654
United States
302 281 2147
https://cardiodiagnosticsinc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, CEO & Director | 307.25k | N/D | 1989 |
Ms. Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer | 275k | N/D | 1964 |
Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer & Director | N/D | N/D | 1962 |
Mr. Timur Dogan Ph.D. | Chief Technology Officer | N/D | N/D | 1988 |
Ms. Khullani Abdullahi J.D. | Vice President of Revenue & Strategy | N/D | N/D | 1984 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
La calificación ISS Governance QuickScore de Cardio Diagnostics Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.